Spotlight on Oncology
Checkpoint Inhibitors as First-line Treatments for Lung Cancer: What You Need to Know
StartActivity Details
Expires: July 27, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is hematologist-oncologists, oncologists, nurses, physician assistants and other health care professionals involved in the management of patients with lung cancer.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Compare available checkpoint inhibitor-based approaches for the management of patients with advanced non–small cell lung cancer (NSCLC) in order to guide individualization of first-line treatment.
- Assess the latest clinical evidence regarding the use of immune checkpoint inhibitors for patients with small cell lung cancer (SCLC), including those with extensive disease.
Activity Description
Lung cancer remains the leading cause of cancer death among both men and women. The American Cancer Society estimates that during 2020, there will be approximately 228,820 new cases of lung cancer and about 135,720 deaths from this disease in the United States. More than half of patients die within 1 year of diagnosis, and the 5-year survival for advanced disease is extremely limited. Utilization of recently approved immune-checkpoint inhibitors (ICIs) in treatment regimens for both non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) has demonstrated clinical benefit and durable responses in some patients, providing a potential for enhanced long-term survival. In this monograph, faculty discuss the use of checkpoint inhibitors in advanced lung cancer, emphasizing new data on the use of these regimens in the first-line setting of advanced disease. Experts will also review appropriate use of ICIs in monotherapy and combination regimens, highlighting new indications for treating NSCLC and SCLC.
Agenda
- Checkpoint Inhibitors for First-line Treatment of Advanced Non–Small Cell Lung Cancer – Mark A. Socinski, MD
- Case Example 1: A Patient With Non–Small Cell Lung Cancer – Mark A. Socinski, MD
- Checkpoint Inhibitors in Small Cell Lung Cancer – Leora Horn, MD, MSc, FRCPC
- Case Example 2: A Patient With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer – Leora Horn, MD, MSc, FRCPC
Faculty
Ingram Associate Professor of Cancer Research
Director Thoracic Oncology Research Program
Vanderbilt Ingram Cancer Center
Nashville, TN
Disclosures:
Consulting Fee: Amgen, AstraZeneca, Bayer, EMD Serono, Genentech-Roche, Incyte, Merck, Pfizer
Executive Medical Director
AdventHealth Cancer Institute
Orlando, FL
Disclosures:
Consulting Fee: AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, Guardant, Merck
Speakers Bureau: AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, Guardant, Merck
Contracted Research: AstraZeneca, Genentech, Novartis, Spectrum
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Medical Writer:
The articles in this ePublication were composed by medical writer
Valerie Zimmerman, PhD, based on the presentations of Drs.
Socinski and Horn at a virtual CME-certified web program recorded on May 28,
2020. The monograph has been approved by each of the authors individually as
an accurate representation of their presentation.
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
This continuing medical education activity is provided by Vindico Medical Education. Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For the purpose of recertifying with ANCC, AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME can be used.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.0 hours credit for completing this program.
This enduring material is approved for 1 year from the date of original release July 28, 2020 to July 27, 2021.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com
Activity Details
Expires: July 27, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is hematologist-oncologists, oncologists, nurses, physician assistants and other health care professionals involved in the management of patients with lung cancer.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Compare available checkpoint inhibitor-based approaches for the management of patients with advanced non–small cell lung cancer (NSCLC) in order to guide individualization of first-line treatment.
- Assess the latest clinical evidence regarding the use of immune checkpoint inhibitors for patients with small cell lung cancer (SCLC), including those with extensive disease.
Activity Description
Lung cancer remains the leading cause of cancer death among both men and women. The American Cancer Society estimates that during 2020, there will be approximately 228,820 new cases of lung cancer and about 135,720 deaths from this disease in the United States. More than half of patients die within 1 year of diagnosis, and the 5-year survival for advanced disease is extremely limited. Utilization of recently approved immune-checkpoint inhibitors (ICIs) in treatment regimens for both non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) has demonstrated clinical benefit and durable responses in some patients, providing a potential for enhanced long-term survival. In this monograph, faculty discuss the use of checkpoint inhibitors in advanced lung cancer, emphasizing new data on the use of these regimens in the first-line setting of advanced disease. Experts will also review appropriate use of ICIs in monotherapy and combination regimens, highlighting new indications for treating NSCLC and SCLC.
Agenda
- Checkpoint Inhibitors for First-line Treatment of Advanced Non–Small Cell Lung Cancer – Mark A. Socinski, MD
- Case Example 1: A Patient With Non–Small Cell Lung Cancer – Mark A. Socinski, MD
- Checkpoint Inhibitors in Small Cell Lung Cancer – Leora Horn, MD, MSc, FRCPC
- Case Example 2: A Patient With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer – Leora Horn, MD, MSc, FRCPC
Faculty
Ingram Associate Professor of Cancer Research
Director Thoracic Oncology Research Program
Vanderbilt Ingram Cancer Center
Nashville, TN
Disclosures:
Consulting Fee: Amgen, AstraZeneca, Bayer, EMD Serono, Genentech-Roche, Incyte, Merck, Pfizer
Executive Medical Director
AdventHealth Cancer Institute
Orlando, FL
Disclosures:
Consulting Fee: AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, Guardant, Merck
Speakers Bureau: AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, Guardant, Merck
Contracted Research: AstraZeneca, Genentech, Novartis, Spectrum
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Medical Writer:
The articles in this ePublication were composed by medical writer
Valerie Zimmerman, PhD, based on the presentations of Drs.
Socinski and Horn at a virtual CME-certified web program recorded on May 28,
2020. The monograph has been approved by each of the authors individually as
an accurate representation of their presentation.
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
This continuing medical education activity is provided by Vindico Medical Education. Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For the purpose of recertifying with ANCC, AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME can be used.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.0 hours credit for completing this program.
This enduring material is approved for 1 year from the date of original release July 28, 2020 to July 27, 2021.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com
Oncology Presentations
Multiple Myeloma Practicums: Caring for Patients in an Ever-Changing Treatment Environment
StartActivity Details
Expires: December 14, 2021
Accredited By
The University of Nebraska Medical Center, Center for Continuing
Education
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.
Learning Objectives
After participating in this activity, participants should be better able to:
- Evaluate various frontline treatment options that are available for the treatment of patients with newly diagnosed MM
- Discuss maintenance therapy options that may be appropriate for patients with MM
- Assess strategies for proper sequencing of agents and regimens in patients with progressive disease
- Review common adverse events that are associated with various treatment strategies and approaches to mitigating such adverse events
Activity Description
This activity will provide expert guidance regarding the treatment of patients with multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents. It is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs.
Statement of Educational Need
Major advances in the diagnosis and treatment of MM have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. As we go forward with these strategies, clinicians treating patients with MM need expert guidance to evaluate best practices and emerging clinical data and plan strategies to apply them safely and effectively to their patients.
Faculty
Chief Medical Officer
Winship Cancer Institute of Emory University
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Emory University School of Medicine
Atlanta, Georgia
Disclosures
Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis.
Conflict of Interest Policy/Disclosure Statement
Faculty and Planning Committee Disclosures
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
All disclosed conflicts of interest have been resolved by independent content review.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.
Accreditation Statement
Continuing Education
The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.
Instructions for Receiving Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Statement of Commercial Support
This activity is supported by independent educational grants from GlaxoSmithKline, Janssen, and Oncopeptides.
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.
Contact Information for Questions About the Activity
info@bioascend.com
Activity Details
Expires: December 14, 2021
Accredited By
The University of Nebraska Medical Center, Center for Continuing
Education
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.
Learning Objectives
After participating in this activity, participants should be better able to:
- Evaluate various frontline treatment options that are available for the treatment of patients with newly diagnosed MM
- Discuss maintenance therapy options that may be appropriate for patients with MM
- Assess strategies for proper sequencing of agents and regimens in patients with progressive disease
- Review common adverse events that are associated with various treatment strategies and approaches to mitigating such adverse events
Activity Description
This activity will provide expert guidance regarding the treatment of patients with multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents. It is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs.
Statement of Educational Need
Major advances in the diagnosis and treatment of MM have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. As we go forward with these strategies, clinicians treating patients with MM need expert guidance to evaluate best practices and emerging clinical data and plan strategies to apply them safely and effectively to their patients.
Faculty
Chief Medical Officer
Winship Cancer Institute of Emory University
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Emory University School of Medicine
Atlanta, Georgia
Disclosures
Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis.
Conflict of Interest Policy/Disclosure Statement
Faculty and Planning Committee Disclosures
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
All disclosed conflicts of interest have been resolved by independent content review.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.
Accreditation Statement
Continuing Education
The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.
Instructions for Receiving Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Statement of Commercial Support
This activity is supported by independent educational grants from GlaxoSmithKline, Janssen, and Oncopeptides.
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.
Contact Information for Questions About the Activity
info@bioascend.com
Integrating New Treatment Options for B-Cell Non-Hodgkin Lymphomas into Practice
StartActivity Details
1.0 Contact Hour(s)
Expires: December 9, 2021
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with B-Cell Non-Hodgkin Lymphomas.
Learning Objectives
After completing this program, participants should be able to:
- Differentiate among emerging and recently approved therapies for B-cell NHLs and review the considerations for their clinical use
- Assess the latest clinical data on new and emerging approaches for treating B-cell NHLs in order to best integrate them into care
- Formulate individualized, evidence-based best-practice treatment plans for patients with B-cell NHLs
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of B-Cell Non-Hodgkin Lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
NHL is one of the most common cancers in the United States, accounting for about 4% of all cancers. This heterogenous group of lymphoproliferative disorders remains a challenge to treat due to differing patterns of behavior and responses to treatment. The ever-changing treatment landscape of NHL provides clinicians new and potentially efficacious approaches with which to treat these challenging cases but selecting a treatment that meets both the clinician’s and the patient’s goals remains challenging. As such, healthcare professionals treating patients with B-cell malignancies will require competency in understanding the application, efficacy, and safety of these new and emerging treatment options to provide sufficient care, support, and treatment.
Faculty
Director of Lymphoma Research Program
Sarah Cannon Research Institute
Tennessee Oncology/OneOncology
Nashville, TN
Conflict of Interest Policy/Disclosure Statement
Dr. Flinn has consulted for:
AbbVie, AstraZeneca, BeiGene, Curio Science, Gilead Science, Great Point
Partners, Iksuda Therapeutics, Janssen, Juno Therapeutics, Kite Pharma,
MorphoSys, Nurix Therapeutics, Pharmacyclics, Roche, Seattle Genetics,
Takeda, TG Therapeutics, Unum Therapeutics, Verastem, Vincera Pharma, Yingli
Pharmaceuticals.
Dr. Flinn has research grants from:
AbbVie, Acerta Pharma, Agios, ArQule, AstraZeneca, BeiGene, Calithera
Biosciences, Celgene, Constellation Pharmaceuticals, Curis, F. Hofman-la
Roche Ltd, Forma Therapeutics, Forty Seven, Genentech, Gilead Sciences, IGM
Biosciences, Incyte, Infinity Pharmaceuticals, Janssen, Juno Therapeutics,
Karyopharm, KITE Pharma, Loxo, Merck, MorphoSys, Novartis, Pfizer,
Pharmacyclics, Portola Pharmaceuticals, Rhizen Pharmaceuticals, Roche,
Seattle Genetics, Takeda, Teva, TG Therapeutics, Trillium Therapeutics,
Triphase Research & Development Corp., Unum Therapeutics, Verastem.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity is being presented without bias and with commercial support.
Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by an educational grant from BMS, Epizyme, Inc. and Janssen Biotech, Inc.
Disclaimer Statement/ Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
Activity Details
1.0 Contact Hour(s)
Expires: December 9, 2021
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with B-Cell Non-Hodgkin Lymphomas.
Learning Objectives
After completing this program, participants should be able to:
- Differentiate among emerging and recently approved therapies for B-cell NHLs and review the considerations for their clinical use
- Assess the latest clinical data on new and emerging approaches for treating B-cell NHLs in order to best integrate them into care
- Formulate individualized, evidence-based best-practice treatment plans for patients with B-cell NHLs
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of B-Cell Non-Hodgkin Lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
NHL is one of the most common cancers in the United States, accounting for about 4% of all cancers. This heterogenous group of lymphoproliferative disorders remains a challenge to treat due to differing patterns of behavior and responses to treatment. The ever-changing treatment landscape of NHL provides clinicians new and potentially efficacious approaches with which to treat these challenging cases but selecting a treatment that meets both the clinician’s and the patient’s goals remains challenging. As such, healthcare professionals treating patients with B-cell malignancies will require competency in understanding the application, efficacy, and safety of these new and emerging treatment options to provide sufficient care, support, and treatment.
Faculty
Director of Lymphoma Research Program
Sarah Cannon Research Institute
Tennessee Oncology/OneOncology
Nashville, TN
Conflict of Interest Policy/Disclosure Statement
Dr. Flinn has consulted for:
AbbVie, AstraZeneca, BeiGene, Curio Science, Gilead Science, Great Point
Partners, Iksuda Therapeutics, Janssen, Juno Therapeutics, Kite Pharma,
MorphoSys, Nurix Therapeutics, Pharmacyclics, Roche, Seattle Genetics,
Takeda, TG Therapeutics, Unum Therapeutics, Verastem, Vincera Pharma, Yingli
Pharmaceuticals.
Dr. Flinn has research grants from:
AbbVie, Acerta Pharma, Agios, ArQule, AstraZeneca, BeiGene, Calithera
Biosciences, Celgene, Constellation Pharmaceuticals, Curis, F. Hofman-la
Roche Ltd, Forma Therapeutics, Forty Seven, Genentech, Gilead Sciences, IGM
Biosciences, Incyte, Infinity Pharmaceuticals, Janssen, Juno Therapeutics,
Karyopharm, KITE Pharma, Loxo, Merck, MorphoSys, Novartis, Pfizer,
Pharmacyclics, Portola Pharmaceuticals, Rhizen Pharmaceuticals, Roche,
Seattle Genetics, Takeda, Teva, TG Therapeutics, Trillium Therapeutics,
Triphase Research & Development Corp., Unum Therapeutics, Verastem.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity is being presented without bias and with commercial support.
Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by an educational grant from BMS, Epizyme, Inc. and Janssen Biotech, Inc.
Disclaimer Statement/ Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
The Expanding Role of BTK Inhibitors for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
StartThe Expanding Role of BTK Inhibitors for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
Activity Details
Expires: December 7, 2021
Accredited By
The University of Nebraska Medical Center, Center for Continuing
Education
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with CLL.
Learning Objectives
After participating in this activity, participants should be better able to:
- Identify the role of BTK signaling in the pathogenesis of CLL, and the rationale for targeting BTK in patients with this malignancy
- Assess clinical trial data of BTK inhibitors that are currently approved for the treatment of patients with CLL
- Evaluate emerging clinical trial data of current and novel BTK inhibitors, including monotherapy and combination approaches
- Review strategies for improving patient outcomes, including optimal selection and sequencing of therapy, as well as oral adherence strategies
Activity Description
Bruton’s tyrosine kinase (BTK) inhibitors are an evolving therapeutic strategy for the treatment of patients with CLL. With multiple BTK inhibitors (and combinations) under investigation and pending approval, clinicians need expert guidance to correctly use these agents safely and effectively for patients with CLL, and plan strategies for optimal integration of these novel agents into practice. This webcast will provide expert interpretation of emerging data and guidance regarding patient diagnosis, treatment, maintenance therapy, and sequencing of agents.
Statement of Educational Need
BTK inhibitors have substantially altered the management, clinical course, and outcome of patients with CLL. This is especially true for patients with previously limited treatment options due to disease characteristics or coexisting diseases. Ibrutinib was the first orally available, nonselective and irreversible inhibitor of BTK approved for the treatment of patients with various B-cell malignancies. Newer and more selective BTK inhibitors are currently in clinical development, including acalabrutinib, which is currently US FDA approved for previously treated mantle cell lymphoma. Significant efforts are underway to investigate the optimal combinations, timing, and sequencing of BTK inhibitors with other regimens and targeted agents, and to capitalize on the immunomodulatory modes of action of BTK inhibitors to correct tumor-induced immune defects and to achieve long-lasting tumor control.
Faculty
Associate Professor of Medicine
Harvard Medical Center
Associate Director, Center for Chronic Lymphocytic Leukemia
Dana-Farber Cancer Institute
Boston, Massachusetts
Disclosures
Contracted Research & Publishing: AbbVie Inc., Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma Inc., Pharmacyclics LLC, Surface Oncology, TG Therapeutics, Verastem, Inc.
Consulting Fees: AbbVie Inc., Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Celgene Corporation, Genentech, Janssen, MEI Pharma Inc., Pharmacyclics LLC, Research to Practice, TG Therapeutics, Verastem, Inc.
Conflict of Interest Policy/Disclosure Statement
Faculty and Planning Committee Disclosures
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
All disclosed conflicts of interest have been resolved by independent content review.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.
Accreditation Statement
Continuing Education
The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.
Instructions for Receiving Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Statement of Commercial Support
This activity is supported by independent educational grants from AstraZeneca, BeiGene and Pharmacyclics.
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.
Contact Information for Questions About the Activity
info@bioascend.com
The Expanding Role of BTK Inhibitors for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
Activity Details
Expires: December 7, 2021
Accredited By
The University of Nebraska Medical Center, Center for Continuing
Education
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with CLL.
Learning Objectives
After participating in this activity, participants should be better able to:
- Identify the role of BTK signaling in the pathogenesis of CLL, and the rationale for targeting BTK in patients with this malignancy
- Assess clinical trial data of BTK inhibitors that are currently approved for the treatment of patients with CLL
- Evaluate emerging clinical trial data of current and novel BTK inhibitors, including monotherapy and combination approaches
- Review strategies for improving patient outcomes, including optimal selection and sequencing of therapy, as well as oral adherence strategies
Activity Description
Bruton’s tyrosine kinase (BTK) inhibitors are an evolving therapeutic strategy for the treatment of patients with CLL. With multiple BTK inhibitors (and combinations) under investigation and pending approval, clinicians need expert guidance to correctly use these agents safely and effectively for patients with CLL, and plan strategies for optimal integration of these novel agents into practice. This webcast will provide expert interpretation of emerging data and guidance regarding patient diagnosis, treatment, maintenance therapy, and sequencing of agents.
Statement of Educational Need
BTK inhibitors have substantially altered the management, clinical course, and outcome of patients with CLL. This is especially true for patients with previously limited treatment options due to disease characteristics or coexisting diseases. Ibrutinib was the first orally available, nonselective and irreversible inhibitor of BTK approved for the treatment of patients with various B-cell malignancies. Newer and more selective BTK inhibitors are currently in clinical development, including acalabrutinib, which is currently US FDA approved for previously treated mantle cell lymphoma. Significant efforts are underway to investigate the optimal combinations, timing, and sequencing of BTK inhibitors with other regimens and targeted agents, and to capitalize on the immunomodulatory modes of action of BTK inhibitors to correct tumor-induced immune defects and to achieve long-lasting tumor control.
Faculty
Associate Professor of Medicine
Harvard Medical Center
Associate Director, Center for Chronic Lymphocytic Leukemia
Dana-Farber Cancer Institute
Boston, Massachusetts
Disclosures
Contracted Research & Publishing: AbbVie Inc., Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma Inc., Pharmacyclics LLC, Surface Oncology, TG Therapeutics, Verastem, Inc.
Consulting Fees: AbbVie Inc., Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Celgene Corporation, Genentech, Janssen, MEI Pharma Inc., Pharmacyclics LLC, Research to Practice, TG Therapeutics, Verastem, Inc.
Conflict of Interest Policy/Disclosure Statement
Faculty and Planning Committee Disclosures
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
All disclosed conflicts of interest have been resolved by independent content review.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.
Accreditation Statement
Continuing Education
The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.
Instructions for Receiving Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Statement of Commercial Support
This activity is supported by independent educational grants from AstraZeneca, BeiGene and Pharmacyclics.
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.
Contact Information for Questions About the Activity
info@bioascend.com
New Choices in Targeted Treatments for Advanced or Metastatic Urothelial Carcinoma: Plot Your Own Course
StartActivity Details
Expires: November 23, 2021
Accredited By
Target Audience
This educational initiative has been designed for genitourinary oncologists, medical oncologists, surgical oncologists, radiologists, urologists, nurse practitioners (NPs), physician assistants (PAs), clinical nurse specialists (CNSs), advanced practice nurses (APNs), oncology clinical nurses (OCNs), and clinical oncology pharmacists (BCOPs) involved in the care and coordination of patients with urothelial carcinoma (UC).
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Articulate the mechanisms of action of targeted biopharmacologics and immune checkpoint inhibitors (ICIs) used in the treatment of UC
- Outline efficacy and safety findings from key clinical trials of approved and investigational novel treatments developed for the treatment of advanced or metastatic UC (mUC)
Statement of Educational Need
In advanced or metastatic urothelial carcinoma (UC) a heavily cytotoxic “sledgehammer” approach has traditionally been used. Platinum-based chemotherapy is still the preferred first-line approach. But this non-specific cytotoxic treatment is often intolerable for the typically older UC patient.
Until recently, there were no second-line options beyond the chemotherapeutic sledgehammer. Today, treatments with more selective mechanisms of action take advantage of fresh translational insights into UC.
These novel therapeutics offer more efficient targeting for patients who have run out of options. But for clinicians, the introduction of these agents complicates an already complex condition. This activity will guide them in selecting and using these options.
In this case-based activity you will navigate a simulated patient case, making clinical decisions when prompted. Feedback regarding your decisions will be provided as you move through the case.
Co-Chairs
Professor, Centre of Experimental Cancer Medicines
Bart’s Cancer Institute
St. Bartholomew’s Hospital
London, United Kingdom
Chief of Clinical Trials
Department of Hematology/Oncology
Vanderbilt University Medical Center
Nashville, Tennessee
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education, Inc requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Thomas Powell, MD:
Consulting Fees: AstraZeneca, Bristol Myers Squibb, Exelixis,
Incyte, Ipsen, Merck/Merck Sharp & Dohme, Novartis, Pfizer, Seattle
Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, and
Roche
Contracted Research: AstraZeneca, Roche, Bristol Myers
Squibb, Exelixis, Ipsen, Merck/Merck Sharp & Dohme, Novartis, Pfizer,
Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, and
Eisai
Other: Expenses/Travel/Accommodation: Roche, Pfizer, Merck
Sharp & Dohme, AstraZeneca, and Ipsen
Brian Rini, MD:
Consulting Fees: Merck, Pfizer, Bristol Myers Squibb, Aravive, AVEO
Pharmaceuticals, GlaxoSmithKline
Contracted Research: Merck, Bristol Myers Squibb, Exelixis,
Pfizer, AstraZeneca
Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
Integrity Continuing Education, Inc is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.
Designation of Credit
Integrity Continuing Education, Inc designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this activity. During the period of November 23, 2020 through November 23, 2021, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc., EMD, Serono, Inc., and Pfizer, Inc. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.
Statement of Commercial Support
Supported by an educational grant from EMD Serono, Inc. and Pfizer, Inc.
Activity Details
Expires: November 23, 2021
Accredited By
Target Audience
This educational initiative has been designed for genitourinary oncologists, medical oncologists, surgical oncologists, radiologists, urologists, nurse practitioners (NPs), physician assistants (PAs), clinical nurse specialists (CNSs), advanced practice nurses (APNs), oncology clinical nurses (OCNs), and clinical oncology pharmacists (BCOPs) involved in the care and coordination of patients with urothelial carcinoma (UC).
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Articulate the mechanisms of action of targeted biopharmacologics and immune checkpoint inhibitors (ICIs) used in the treatment of UC
- Outline efficacy and safety findings from key clinical trials of approved and investigational novel treatments developed for the treatment of advanced or metastatic UC (mUC)
Statement of Educational Need
In advanced or metastatic urothelial carcinoma (UC) a heavily cytotoxic “sledgehammer” approach has traditionally been used. Platinum-based chemotherapy is still the preferred first-line approach. But this non-specific cytotoxic treatment is often intolerable for the typically older UC patient.
Until recently, there were no second-line options beyond the chemotherapeutic sledgehammer. Today, treatments with more selective mechanisms of action take advantage of fresh translational insights into UC.
These novel therapeutics offer more efficient targeting for patients who have run out of options. But for clinicians, the introduction of these agents complicates an already complex condition. This activity will guide them in selecting and using these options.
In this case-based activity you will navigate a simulated patient case, making clinical decisions when prompted. Feedback regarding your decisions will be provided as you move through the case.
Co-Chairs
Professor, Centre of Experimental Cancer Medicines
Bart’s Cancer Institute
St. Bartholomew’s Hospital
London, United Kingdom
Chief of Clinical Trials
Department of Hematology/Oncology
Vanderbilt University Medical Center
Nashville, Tennessee
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education, Inc requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Thomas Powell, MD:
Consulting Fees: AstraZeneca, Bristol Myers Squibb, Exelixis,
Incyte, Ipsen, Merck/Merck Sharp & Dohme, Novartis, Pfizer, Seattle
Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, and
Roche
Contracted Research: AstraZeneca, Roche, Bristol Myers
Squibb, Exelixis, Ipsen, Merck/Merck Sharp & Dohme, Novartis, Pfizer,
Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, and
Eisai
Other: Expenses/Travel/Accommodation: Roche, Pfizer, Merck
Sharp & Dohme, AstraZeneca, and Ipsen
Brian Rini, MD:
Consulting Fees: Merck, Pfizer, Bristol Myers Squibb, Aravive, AVEO
Pharmaceuticals, GlaxoSmithKline
Contracted Research: Merck, Bristol Myers Squibb, Exelixis,
Pfizer, AstraZeneca
Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
Integrity Continuing Education, Inc is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.
Designation of Credit
Integrity Continuing Education, Inc designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this activity. During the period of November 23, 2020 through November 23, 2021, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc., EMD, Serono, Inc., and Pfizer, Inc. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.
Statement of Commercial Support
Supported by an educational grant from EMD Serono, Inc. and Pfizer, Inc.
The Expanding Treatment Landscape of Waldenström’s Macroglobulinemia
StartActivity Details
1.0 Contact Hour(s)
Expires: October 27, 2021
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Waldenström’s Macroglobulinemia.
Learning Objectives
After completing this program, participants should be able to:
- Summarize criteria required to accurately diagnose patients with Waldenström’s macroglobulinemia and identify those most likely to benefit from treatment
- Evaluate the latest clinical data on the efficacy and safety of approved and investigational therapies for patients with Waldenström’s macroglobulinemia
- Formulate best-practice treatment strategies for patients with Waldenström’s macroglobulinemia, taking into consideration current guidelines and expert recommendations when individualizing treatment plans
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of Waldenström’s Macroglobulinemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
With the recent advances in targeted therapies for WM, the use of approved and investigational agents is anticipated to expand over the coming years. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the appropriate diagnosis and risk stratification of patients with WM and the clinical utility of agents that could significantly impact patient outcomes.
Faculty
Director, Bing Center for Waldenström's Macroglobulinemia
Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA
Conflict of Interest Policy/Disclosure Statement
Dr. Treon has consulted for Janssen Pharmaceuticals, Inc., Pharmacyclics, Inc., and BeiGene, Inc.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only credit commensurate with the extent of their
participation in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of 1.0 continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of 1.0 continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by an educational grant from Janssen Biotech, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
Activity Details
1.0 Contact Hour(s)
Expires: October 27, 2021
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Waldenström’s Macroglobulinemia.
Learning Objectives
After completing this program, participants should be able to:
- Summarize criteria required to accurately diagnose patients with Waldenström’s macroglobulinemia and identify those most likely to benefit from treatment
- Evaluate the latest clinical data on the efficacy and safety of approved and investigational therapies for patients with Waldenström’s macroglobulinemia
- Formulate best-practice treatment strategies for patients with Waldenström’s macroglobulinemia, taking into consideration current guidelines and expert recommendations when individualizing treatment plans
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of Waldenström’s Macroglobulinemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
With the recent advances in targeted therapies for WM, the use of approved and investigational agents is anticipated to expand over the coming years. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the appropriate diagnosis and risk stratification of patients with WM and the clinical utility of agents that could significantly impact patient outcomes.
Faculty
Director, Bing Center for Waldenström's Macroglobulinemia
Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA
Conflict of Interest Policy/Disclosure Statement
Dr. Treon has consulted for Janssen Pharmaceuticals, Inc., Pharmacyclics, Inc., and BeiGene, Inc.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only credit commensurate with the extent of their
participation in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of 1.0 continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of 1.0 continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by an educational grant from Janssen Biotech, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
Tales from the Trenches: COVID-19’s Impact on Cancer Care
StartActivity Details
ANCC Credit(s)
Expires: August 21, 2021
Accredited By
Target Audience
This activity is intended for medical oncologists, oncology nurses, and other healthcare providers who care for patients with cancer, as well as healthcare administrators.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Discuss the risk of infection and severity of illness with COVID-19 across varied patient populations with hematologic and solid tumor malignancies
- Identify COVID-19 risk mitigation strategies at cancer care facilities, including optimal telemedicine practices
- Assess guideline-recommended strategies to optimize and individualize treatment protocols for cancer patients infected with COVID-19
Activity Description
The unprecedented era that healthcare providers around the world are facing given the COVID-19 pandemic leaves countless unanswered questions, forcing clinicians and cancer patients to adapt to the current environment. How can clinicians be assured they stay apprised of rapidly evolving data during COVID-19 and consider implications to cancer care?
Mia Levy, MD, PhD, System Vice President for Cancer Services at Rush System for Health, leads discussions with expert Rush University Medical Center oncology, infectious disease, critical care, and administrative panel experts in these commentary segments. These expert panel segments relay the latest information and provide real-world experiences on how a major health system is addressing and adjusting to the current environment on COVID-19’s impact on cancer care.
Statement of Educational Need
Proper knowledge on COVID-19 risk mitigation, identification, and therapeutic management for oncology patients is critical during the pandemic. The purpose of the activity is to hear the latest tales from the trenches surrounding COVID-19 and discuss the pandemic’s implications for managing patients with cancer, including the practical application of telehealth services. Upon completion of this activity, clinicians will be better able to implement recommended practices to mitigate risks from COVID-19 complications and be better aware of COVID-19-related practice changes that will impact their oncology patients and telehealth practices.
Agenda
Discover Tales from the Trenches Topics:
- The Latest Epidemiological Data: Cancer and COVID-19
- Mitigating Risks at Cancer Care Facilities
- Therapeutic Management During the Pandemic and COVID-19 Infection
- Continuity of Care in Oncology Practices
- Optimizing Telemedicine
Faculty
The Sheba Foundation Director of the
Cancer Center at Rush University Medical Center
System Vice President for Cancer Services
Rush System for Health
Chicago, IL
Alice Pirie Wirtz Professor of Medicine
Rush Medical College
Chicago, IL
Associate Professor of Medicine
Director, Hematology Oncology Fellowship Program
Director, Leukemia Program
Section of Hematology
Division of Hematology, Oncology and Cell Therapy
Rush University Medical Center
Chicago, IL
Associate Professor
Department of Internal Medicine,
Division of Infectious Diseases
Hospital Epidemiologist
Rush University Medical Center
Chicago, IL
Associate Vice President of Nursing,
Oncology Service Line
Rush University Medical Center
Chicago, IL
System Vice President
and Chief Administrative Officer, Oncology
Rush University System for Health
Chicago, IL
Associate Professor
Department of Internal Medicine
Medical Director,
Medical Intensive Care Unit
Rush University Medical Center
Chicago, IL
Conflict of Interest Policy/Disclosure Statement
As a provider of continuing education, Rush University Medical Center asks everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. This includes any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by or used on patients. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months, including financial relationships of a spouse or life partner that could create a conflict of interest. Mechanisms are in place to identify and resolve any potential conflict of interest prior to the start of the activity.
Disclosure Statement (potential conflict to disclose):
Philip D. Bonomi, MD (faculty) discloses that he has Consulting Agreements with AstraZeneca, Merck, Pfizer Inc., and Spectrum Pharmaceuticals.
The remaining course director(s), planner(s), faculty, and reviewer(s) of this activity have no relevant financial relationships to disclose.
Melissa Larson, MD (Faculty)
Mia Levy, MD, PhD (Moderator)
Michael Lin, MD, MPH (Faculty)
Sharon Manson, RN, MS, ACNP (Faculty)
Katharine Conklin Struck, JD (Faculty)
Mark Yoder, MD, MS (Faculty)
Unapproved Uses of Drugs/Devices
In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.
Staff Disclosure
Rush University Medical Center and ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
Accreditation Statement
In support of improving patient care, Rush University
Medical Center is jointly accredited by the Accreditation Council for
Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy
Education (ACPE), and the American Nurses Credentialing Center (ANCC), to
provide continuing education for the healthcare team.
This activity is being presented without bias and with commercial support.
Designation of Credit
Rush University Medical Center designates this internet enduring material activity for a maximum of (2) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
ANCC Credit Designation Statement
Rush University Medical Center designates this internet enduring material for a maximum of (2) nursing contact hour(s).
Instructions for Receiving Credit
This activity will take approximately 120 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Statement of Commercial Support
Supported by educational grants from AbbVie Inc., Astellas, AstraZeneca, Lilly, and Pfizer Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
Contact Information for Questions About the Activity
For questions, contact Michelle Forcier at mforcier@achlcme.org
Activity Details
ANCC Credit(s)
Expires: August 21, 2021
Accredited By
Target Audience
This activity is intended for medical oncologists, oncology nurses, and other healthcare providers who care for patients with cancer, as well as healthcare administrators.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Discuss the risk of infection and severity of illness with COVID-19 across varied patient populations with hematologic and solid tumor malignancies
- Identify COVID-19 risk mitigation strategies at cancer care facilities, including optimal telemedicine practices
- Assess guideline-recommended strategies to optimize and individualize treatment protocols for cancer patients infected with COVID-19
Activity Description
The unprecedented era that healthcare providers around the world are facing given the COVID-19 pandemic leaves countless unanswered questions, forcing clinicians and cancer patients to adapt to the current environment. How can clinicians be assured they stay apprised of rapidly evolving data during COVID-19 and consider implications to cancer care?
Mia Levy, MD, PhD, System Vice President for Cancer Services at Rush System for Health, leads discussions with expert Rush University Medical Center oncology, infectious disease, critical care, and administrative panel experts in these commentary segments. These expert panel segments relay the latest information and provide real-world experiences on how a major health system is addressing and adjusting to the current environment on COVID-19’s impact on cancer care.
Statement of Educational Need
Proper knowledge on COVID-19 risk mitigation, identification, and therapeutic management for oncology patients is critical during the pandemic. The purpose of the activity is to hear the latest tales from the trenches surrounding COVID-19 and discuss the pandemic’s implications for managing patients with cancer, including the practical application of telehealth services. Upon completion of this activity, clinicians will be better able to implement recommended practices to mitigate risks from COVID-19 complications and be better aware of COVID-19-related practice changes that will impact their oncology patients and telehealth practices.
Agenda
Discover Tales from the Trenches Topics:
- The Latest Epidemiological Data: Cancer and COVID-19
- Mitigating Risks at Cancer Care Facilities
- Therapeutic Management During the Pandemic and COVID-19 Infection
- Continuity of Care in Oncology Practices
- Optimizing Telemedicine
Faculty
The Sheba Foundation Director of the
Cancer Center at Rush University Medical Center
System Vice President for Cancer Services
Rush System for Health
Chicago, IL
Alice Pirie Wirtz Professor of Medicine
Rush Medical College
Chicago, IL
Associate Professor of Medicine
Director, Hematology Oncology Fellowship Program
Director, Leukemia Program
Section of Hematology
Division of Hematology, Oncology and Cell Therapy
Rush University Medical Center
Chicago, IL
Associate Professor
Department of Internal Medicine,
Division of Infectious Diseases
Hospital Epidemiologist
Rush University Medical Center
Chicago, IL
Associate Vice President of Nursing,
Oncology Service Line
Rush University Medical Center
Chicago, IL
System Vice President
and Chief Administrative Officer, Oncology
Rush University System for Health
Chicago, IL
Associate Professor
Department of Internal Medicine
Medical Director,
Medical Intensive Care Unit
Rush University Medical Center
Chicago, IL
Conflict of Interest Policy/Disclosure Statement
As a provider of continuing education, Rush University Medical Center asks everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. This includes any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by or used on patients. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months, including financial relationships of a spouse or life partner that could create a conflict of interest. Mechanisms are in place to identify and resolve any potential conflict of interest prior to the start of the activity.
Disclosure Statement (potential conflict to disclose):
Philip D. Bonomi, MD (faculty) discloses that he has Consulting Agreements with AstraZeneca, Merck, Pfizer Inc., and Spectrum Pharmaceuticals.
The remaining course director(s), planner(s), faculty, and reviewer(s) of this activity have no relevant financial relationships to disclose.
Melissa Larson, MD (Faculty)
Mia Levy, MD, PhD (Moderator)
Michael Lin, MD, MPH (Faculty)
Sharon Manson, RN, MS, ACNP (Faculty)
Katharine Conklin Struck, JD (Faculty)
Mark Yoder, MD, MS (Faculty)
Unapproved Uses of Drugs/Devices
In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.
Staff Disclosure
Rush University Medical Center and ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
Accreditation Statement
In support of improving patient care, Rush University
Medical Center is jointly accredited by the Accreditation Council for
Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy
Education (ACPE), and the American Nurses Credentialing Center (ANCC), to
provide continuing education for the healthcare team.
This activity is being presented without bias and with commercial support.
Designation of Credit
Rush University Medical Center designates this internet enduring material activity for a maximum of (2) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
ANCC Credit Designation Statement
Rush University Medical Center designates this internet enduring material for a maximum of (2) nursing contact hour(s).
Instructions for Receiving Credit
This activity will take approximately 120 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Statement of Commercial Support
Supported by educational grants from AbbVie Inc., Astellas, AstraZeneca, Lilly, and Pfizer Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
Contact Information for Questions About the Activity
For questions, contact Michelle Forcier at mforcier@achlcme.org
Expert Insights: The Expanding Role of Immunotherapy for the Treatment of Multiple Myeloma - Focus on Antibodies, Antibody-Drug Conjugates, and CAR T-Cells
StartActivity Details
Expires: August 3, 2021
Accredited By
The University of Nebraska Medical Center, Center for Continuing Education
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.
Learning Objectives
After participating in this activity, participants should be better able to:
- Review unmet needs in the care of multiple myeloma (MM) and the potential role of immunotherapies such as antibodies, antibody-drug conjugates, CAR T-cells, and others
- Evaluate clinical trial data of current and emerging immunotherapies being examined in patients with MM
- Assess unique adverse event profiles of immunotherapies that differ from traditional therapies used for the treatment of patients with MM
- Develop strategies to integrate immunotherapies into the MM treatment paradigm as they become available
Activity Description
Expert Insights is a summary of a virtual satellite symposium from the 2020 Clinical Oncology Meeting and will discuss current data of current and emerging immunotherapeutic-based approaches for the treatment of patients with multiple myeloma.
Statement of Educational Need
Given the recent approval of immunotherapies for the treatment of patients with multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs. Thus, we propose to facilitate evaluation of emerging scientific and clinical data, and appropriate use of current and emerging therapies, by clinicians who treat patients with MM.
Agenda
- Unmet needs
- Monoclonal antibodies
- BiTEs
- Vaccines
- ADCs
- CAR T-cells
Faculty
Chief, Plasma Cell Disorders Division
Director, Clinical Research in Hematologic Malignancies
Department of Hematologic Oncology & Blood Disorders
Levine Cancer Institute
Charlotte, North Carolina
Consulting Fees: Amgen Inc., Bristol Myers Squibb, Celgene Corporation, GlaxoSmithKline, Janssen Oncology, Merck & Co., Sanofi, SkylineDX, Takeda Pharmaceutical Company
Contracted Research & Publishing: Amgen Inc., Array BioPharma, Bristol Myers Squibb, Celgene Corporation, GlaxoSmithKline, Janssen Oncology, Merck & Co., Pharmacyclics LLC, Sanofi, Seattle Genetics, SkylineDX, Takeda Pharmaceutical Company
Speaker’s Bureau: Amgen Inc., Celgene Corporation, Janssen Oncology, Sanofi, Takeda Pharmaceutical Company
Assistant Professor
Department of Lymphoma and Myeloma
Assistant Professor
Department of Stem Cell Transplantation
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Consulting Fees: Bristol Myers Squibb, Celgene Corporation, Cellectis, Janssen Oncology, Nektar Therapeutics, Pfizer Inc., Poseida Therapeutics, Inc., Precision BioSciences
Contracted Research & Publishing: AbbVie Inc., Bristol Myers Squibb, Celgene Corporation, Cellectis, Janssen Oncology, Nektar Therapeutics, Poseida Therapeutics, Inc., Precision BioSciences
Conflict of Interest Policy/Disclosure Statement
Faculty and Planning Committee Disclosures
As a provider accredited by ACCME, the UNMC Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.
Accreditation Statement
Continuing Education
The University of Nebraska Medical Center (UNMC), Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The UNMC Center for Continuing Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of the UNMC Center for Continuing Education and Bio Ascend.
Instructions for Receiving Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Materials will be available online through August 3, 2021.
Statement of Commercial Support
This activity is supported by independent educational grants from Legend Biotech and Sanofi Genzyme.
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.
Contact Information for Questions About the Activity
cme@bioascend.com
Activity Details
Expires: August 3, 2021
Accredited By
The University of Nebraska Medical Center, Center for Continuing Education
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.
Learning Objectives
After participating in this activity, participants should be better able to:
- Review unmet needs in the care of multiple myeloma (MM) and the potential role of immunotherapies such as antibodies, antibody-drug conjugates, CAR T-cells, and others
- Evaluate clinical trial data of current and emerging immunotherapies being examined in patients with MM
- Assess unique adverse event profiles of immunotherapies that differ from traditional therapies used for the treatment of patients with MM
- Develop strategies to integrate immunotherapies into the MM treatment paradigm as they become available
Activity Description
Expert Insights is a summary of a virtual satellite symposium from the 2020 Clinical Oncology Meeting and will discuss current data of current and emerging immunotherapeutic-based approaches for the treatment of patients with multiple myeloma.
Statement of Educational Need
Given the recent approval of immunotherapies for the treatment of patients with multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs. Thus, we propose to facilitate evaluation of emerging scientific and clinical data, and appropriate use of current and emerging therapies, by clinicians who treat patients with MM.
Agenda
- Unmet needs
- Monoclonal antibodies
- BiTEs
- Vaccines
- ADCs
- CAR T-cells
Faculty
Chief, Plasma Cell Disorders Division
Director, Clinical Research in Hematologic Malignancies
Department of Hematologic Oncology & Blood Disorders
Levine Cancer Institute
Charlotte, North Carolina
Consulting Fees: Amgen Inc., Bristol Myers Squibb, Celgene Corporation, GlaxoSmithKline, Janssen Oncology, Merck & Co., Sanofi, SkylineDX, Takeda Pharmaceutical Company
Contracted Research & Publishing: Amgen Inc., Array BioPharma, Bristol Myers Squibb, Celgene Corporation, GlaxoSmithKline, Janssen Oncology, Merck & Co., Pharmacyclics LLC, Sanofi, Seattle Genetics, SkylineDX, Takeda Pharmaceutical Company
Speaker’s Bureau: Amgen Inc., Celgene Corporation, Janssen Oncology, Sanofi, Takeda Pharmaceutical Company
Assistant Professor
Department of Lymphoma and Myeloma
Assistant Professor
Department of Stem Cell Transplantation
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Consulting Fees: Bristol Myers Squibb, Celgene Corporation, Cellectis, Janssen Oncology, Nektar Therapeutics, Pfizer Inc., Poseida Therapeutics, Inc., Precision BioSciences
Contracted Research & Publishing: AbbVie Inc., Bristol Myers Squibb, Celgene Corporation, Cellectis, Janssen Oncology, Nektar Therapeutics, Poseida Therapeutics, Inc., Precision BioSciences
Conflict of Interest Policy/Disclosure Statement
Faculty and Planning Committee Disclosures
As a provider accredited by ACCME, the UNMC Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.
Accreditation Statement
Continuing Education
The University of Nebraska Medical Center (UNMC), Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The UNMC Center for Continuing Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of the UNMC Center for Continuing Education and Bio Ascend.
Instructions for Receiving Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Materials will be available online through August 3, 2021.
Statement of Commercial Support
This activity is supported by independent educational grants from Legend Biotech and Sanofi Genzyme.
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.
Contact Information for Questions About the Activity
cme@bioascend.com
Clinical Transfers℠: State-of-the-Art Management for NSCLC: Novel Targets and Therapies
StartActivity Details
ABIM MOC point(s)
Expires: July 30, 2021
Accredited By
Target Audience
This activity is designed to meet the educational needs of oncology and pathology clinicians involved in the treatment of patients with non-small cell lung cancer (NSCLC).
Learning Objectives
- Assess the potential role of novel therapies directed against TROP2 and other emerging targets in the management of non-small cell lung cancer (NSCLC)
- Identify the potential impact of HER2-/3-directed therapies on the current NSCLC treatment algorithm
Activity Description
The landscape of precision medicine for non-small cell lung cancer (NSCLC) is continually evolving with an ever-expanding armamentarium of targeted agents. This educational activity is designed to provide a synopsis of novel targets and therapies. Jacob Sands, MD, a thoracic medical oncologist, will provide the latest data for newly approved and investigational MET and RET inhibitors, as well as the latest evidence for drug-antibody conjugates directed towards HER2, HER3, TROP2, and B7-H3.
Statement of Commercial Support
The rapid development of novel targets and therapies for NSCLC exemplifies the precision medicine approach in clinical oncology. The first MET and RET inhibitors have recently joined the ever-expanding treatment armamentarium, and others are currently in development. Data is emerging for antibody-drug conjugates designed to target HER2, HER3, TROP2, and B7-H3. Expert guidance is needed to stay abreast of this continually evolving and increasingly complex therapeutic landscape in order to provide optimal patient care and potentially enroll eligible patients into clinical trials.
Agenda
- 1. The importance of broad molecular profiling in NSCLC.
- 2. Recently presented data for currently approved and investigational MET and RET inhibitors.
- 3. Recently presented data for drug-antibody conjugates targeting HER2, HER3, TROP2, and B7-H3.
- 4. Summary
Faculty
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA
Jacob Sands, MD received his MD from the University of Cincinnati in 2005. He completed both residency in internal medicine and fellowship training in hematology/oncology at the University of California, Davis. He joined Dana-Farber Cancer Institute in 2017 where he treats patients with lung cancer and leads clinical research, including an NCI-sponsored study evaluating incorporation of checkpoint inhibitor into adjuvant therapy for non-small cell lung cancer. Dr. Sands leads the small cell lung cancer program at Dana-Farber Cancer Institute and sits on the NCCN guidelines committee for small cell lung cancer as well as the guidelines committee for lung screening. Dr. Sands is a member of the IASLC Screening & Early Detection Committee, a scientific advisory board member of the GO2 Foundation for Lung Cancer, a media spokesperson for the American Lung Association, and Treasurer of the Rescue Lung Rescue Life Society.
Conflict of Interest Policy/Disclosure Statement
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Jacob Sands, MD, has affiliations with AstraZeneca, Boehringer Ingelheim, Jazz Pharmaceuticals, Lilly, Medtronic, Pharma Mar (Consulting Fees); Merck (Research).
Planners and Managers
The Postgraduate Institute for Medicine planners and managers
have nothing to disclose. The RMEI Medical Education, LLC planners and
managers have nothing to disclose.
Accreditation Statement
In
support of improving patient care, this activity has been planned and
implemented by the Postgraduate Institute for Medicine, and RMEI Medical
Education, LLC. Postgraduate Institute for Medicine is jointly accredited by
the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There is no fee for this educational activity.
During the period July 31, 2020 through July 30, 2021, participants must:
- 1. Read the learning objectives and disclosures
- 2. Study the educational activity
- 3. Complete the evaluation form
Select the desired certificate and click on Submit. Click on Download Certificate and print the certificate for your records.
Accreditation Support
Please contact Postgraduate Institute for Medicine Continuing Medical
Education Department at inquiries@pimed.com or by calling
303-799-1930
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a
full-service medical education company. The winner will be selected via
automated random drawing on a monthly basis from among all eligible entries
and notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation forms and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Daiichi Sankyo, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. The
planners of this activity do not recommend the use of any agent outside of
the labeled indications. The opinions expressed in the educational activity
are those of the faculty and do not necessarily represent the views of the
planners. Please refer to the official prescribing information for each
product for discussion of approved indications, contraindications, and
warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired
information to enhance patient outcomes and their own professional
development. The information presented in this activity is not meant to serve
as a guideline for patient management. Any procedures, medications, or other
courses of diagnosis or treatment discussed or suggested in this activity
should not be used by clinicians without evaluation of their patient’s
conditions and possible contraindications on dangers in use, review of any
applicable manufacturer’s product information, and comparison with
recommendations of other authorities.
Contact Information for Questions about the Activity
Please contact Nicole Neely at nneely@rmei.com for questions regarding this activity.
Activity Details
ABIM MOC point(s)
Expires: July 30, 2021
Accredited By
Target Audience
This activity is designed to meet the educational needs of oncology and pathology clinicians involved in the treatment of patients with non-small cell lung cancer (NSCLC).
Learning Objectives
- Assess the potential role of novel therapies directed against TROP2 and other emerging targets in the management of non-small cell lung cancer (NSCLC)
- Identify the potential impact of HER2-/3-directed therapies on the current NSCLC treatment algorithm
Activity Description
The landscape of precision medicine for non-small cell lung cancer (NSCLC) is continually evolving with an ever-expanding armamentarium of targeted agents. This educational activity is designed to provide a synopsis of novel targets and therapies. Jacob Sands, MD, a thoracic medical oncologist, will provide the latest data for newly approved and investigational MET and RET inhibitors, as well as the latest evidence for drug-antibody conjugates directed towards HER2, HER3, TROP2, and B7-H3.
Statement of Commercial Support
The rapid development of novel targets and therapies for NSCLC exemplifies the precision medicine approach in clinical oncology. The first MET and RET inhibitors have recently joined the ever-expanding treatment armamentarium, and others are currently in development. Data is emerging for antibody-drug conjugates designed to target HER2, HER3, TROP2, and B7-H3. Expert guidance is needed to stay abreast of this continually evolving and increasingly complex therapeutic landscape in order to provide optimal patient care and potentially enroll eligible patients into clinical trials.
Agenda
- 1. The importance of broad molecular profiling in NSCLC.
- 2. Recently presented data for currently approved and investigational MET and RET inhibitors.
- 3. Recently presented data for drug-antibody conjugates targeting HER2, HER3, TROP2, and B7-H3.
- 4. Summary
Faculty
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA
Jacob Sands, MD received his MD from the University of Cincinnati in 2005. He completed both residency in internal medicine and fellowship training in hematology/oncology at the University of California, Davis. He joined Dana-Farber Cancer Institute in 2017 where he treats patients with lung cancer and leads clinical research, including an NCI-sponsored study evaluating incorporation of checkpoint inhibitor into adjuvant therapy for non-small cell lung cancer. Dr. Sands leads the small cell lung cancer program at Dana-Farber Cancer Institute and sits on the NCCN guidelines committee for small cell lung cancer as well as the guidelines committee for lung screening. Dr. Sands is a member of the IASLC Screening & Early Detection Committee, a scientific advisory board member of the GO2 Foundation for Lung Cancer, a media spokesperson for the American Lung Association, and Treasurer of the Rescue Lung Rescue Life Society.
Conflict of Interest Policy/Disclosure Statement
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Jacob Sands, MD, has affiliations with AstraZeneca, Boehringer Ingelheim, Jazz Pharmaceuticals, Lilly, Medtronic, Pharma Mar (Consulting Fees); Merck (Research).
Planners and Managers
The Postgraduate Institute for Medicine planners and managers
have nothing to disclose. The RMEI Medical Education, LLC planners and
managers have nothing to disclose.
Accreditation Statement
In
support of improving patient care, this activity has been planned and
implemented by the Postgraduate Institute for Medicine, and RMEI Medical
Education, LLC. Postgraduate Institute for Medicine is jointly accredited by
the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There is no fee for this educational activity.
During the period July 31, 2020 through July 30, 2021, participants must:
- 1. Read the learning objectives and disclosures
- 2. Study the educational activity
- 3. Complete the evaluation form
Select the desired certificate and click on Submit. Click on Download Certificate and print the certificate for your records.
Accreditation Support
Please contact Postgraduate Institute for Medicine Continuing Medical
Education Department at inquiries@pimed.com or by calling
303-799-1930
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a
full-service medical education company. The winner will be selected via
automated random drawing on a monthly basis from among all eligible entries
and notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation forms and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Daiichi Sankyo, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. The
planners of this activity do not recommend the use of any agent outside of
the labeled indications. The opinions expressed in the educational activity
are those of the faculty and do not necessarily represent the views of the
planners. Please refer to the official prescribing information for each
product for discussion of approved indications, contraindications, and
warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired
information to enhance patient outcomes and their own professional
development. The information presented in this activity is not meant to serve
as a guideline for patient management. Any procedures, medications, or other
courses of diagnosis or treatment discussed or suggested in this activity
should not be used by clinicians without evaluation of their patient’s
conditions and possible contraindications on dangers in use, review of any
applicable manufacturer’s product information, and comparison with
recommendations of other authorities.
Contact Information for Questions about the Activity
Please contact Nicole Neely at nneely@rmei.com for questions regarding this activity.
Checkpoint Inhibitors as First-line Treatments for Lung Cancer: What You Need to Know
StartActivity Details
Expires: July 27, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is hematologist-oncologists, oncologists, nurses, physician assistants and other health care professionals involved in the management of patients with lung cancer.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Compare available checkpoint inhibitor-based approaches for the management of patients with advanced non–small cell lung cancer (NSCLC) in order to guide individualization of first-line treatment.
- Assess the latest clinical evidence regarding the use of immune checkpoint inhibitors for patients with small cell lung cancer (SCLC), including those with extensive disease.
Activity Description
Lung cancer remains the leading cause of cancer death among both men and women. The American Cancer Society estimates that during 2020, there will be approximately 228,820 new cases of lung cancer and about 135,720 deaths from this disease in the United States. More than half of patients die within 1 year of diagnosis, and the 5-year survival for advanced disease is extremely limited. Utilization of recently approved immune-checkpoint inhibitors (ICIs) in treatment regimens for both non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) has demonstrated clinical benefit and durable responses in some patients, providing a potential for enhanced long-term survival. In this monograph, faculty discuss the use of checkpoint inhibitors in advanced lung cancer, emphasizing new data on the use of these regimens in the first-line setting of advanced disease. Experts will also review appropriate use of ICIs in monotherapy and combination regimens, highlighting new indications for treating NSCLC and SCLC.
Agenda
- Checkpoint Inhibitors for First-line Treatment of Advanced Non–Small Cell Lung Cancer – Mark A. Socinski, MD
- Case Example 1: A Patient With Non–Small Cell Lung Cancer – Mark A. Socinski, MD
- Checkpoint Inhibitors in Small Cell Lung Cancer – Leora Horn, MD, MSc, FRCPC
- Case Example 2: A Patient With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer – Leora Horn, MD, MSc, FRCPC
Faculty
Ingram Associate Professor of Cancer Research
Director Thoracic Oncology Research Program
Vanderbilt Ingram Cancer Center
Nashville, TN
Disclosures:
Consulting Fee: Amgen, AstraZeneca, Bayer, EMD Serono, Genentech-Roche, Incyte, Merck, Pfizer
Executive Medical Director
AdventHealth Cancer Institute
Orlando, FL
Disclosures:
Consulting Fee: AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, Guardant, Merck
Speakers Bureau: AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, Guardant, Merck
Contracted Research: AstraZeneca, Genentech, Novartis, Spectrum
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Medical Writer:
The articles in this ePublication were composed by medical writer
Valerie Zimmerman, PhD, based on the presentations of Drs.
Socinski and Horn at a virtual CME-certified web program recorded on May 28,
2020. The monograph has been approved by each of the authors individually as
an accurate representation of their presentation.
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
This continuing medical education activity is provided by Vindico Medical Education. Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For the purpose of recertifying with ANCC, AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME can be used.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.0 hours credit for completing this program.
This enduring material is approved for 1 year from the date of original release July 28, 2020 to July 27, 2021.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com
Activity Details
Expires: July 27, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is hematologist-oncologists, oncologists, nurses, physician assistants and other health care professionals involved in the management of patients with lung cancer.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Compare available checkpoint inhibitor-based approaches for the management of patients with advanced non–small cell lung cancer (NSCLC) in order to guide individualization of first-line treatment.
- Assess the latest clinical evidence regarding the use of immune checkpoint inhibitors for patients with small cell lung cancer (SCLC), including those with extensive disease.
Activity Description
Lung cancer remains the leading cause of cancer death among both men and women. The American Cancer Society estimates that during 2020, there will be approximately 228,820 new cases of lung cancer and about 135,720 deaths from this disease in the United States. More than half of patients die within 1 year of diagnosis, and the 5-year survival for advanced disease is extremely limited. Utilization of recently approved immune-checkpoint inhibitors (ICIs) in treatment regimens for both non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) has demonstrated clinical benefit and durable responses in some patients, providing a potential for enhanced long-term survival. In this monograph, faculty discuss the use of checkpoint inhibitors in advanced lung cancer, emphasizing new data on the use of these regimens in the first-line setting of advanced disease. Experts will also review appropriate use of ICIs in monotherapy and combination regimens, highlighting new indications for treating NSCLC and SCLC.
Agenda
- Checkpoint Inhibitors for First-line Treatment of Advanced Non–Small Cell Lung Cancer – Mark A. Socinski, MD
- Case Example 1: A Patient With Non–Small Cell Lung Cancer – Mark A. Socinski, MD
- Checkpoint Inhibitors in Small Cell Lung Cancer – Leora Horn, MD, MSc, FRCPC
- Case Example 2: A Patient With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer – Leora Horn, MD, MSc, FRCPC
Faculty
Ingram Associate Professor of Cancer Research
Director Thoracic Oncology Research Program
Vanderbilt Ingram Cancer Center
Nashville, TN
Disclosures:
Consulting Fee: Amgen, AstraZeneca, Bayer, EMD Serono, Genentech-Roche, Incyte, Merck, Pfizer
Executive Medical Director
AdventHealth Cancer Institute
Orlando, FL
Disclosures:
Consulting Fee: AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, Guardant, Merck
Speakers Bureau: AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, Guardant, Merck
Contracted Research: AstraZeneca, Genentech, Novartis, Spectrum
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Medical Writer:
The articles in this ePublication were composed by medical writer
Valerie Zimmerman, PhD, based on the presentations of Drs.
Socinski and Horn at a virtual CME-certified web program recorded on May 28,
2020. The monograph has been approved by each of the authors individually as
an accurate representation of their presentation.
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
This continuing medical education activity is provided by Vindico Medical Education. Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For the purpose of recertifying with ANCC, AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME can be used.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.0 hours credit for completing this program.
This enduring material is approved for 1 year from the date of original release July 28, 2020 to July 27, 2021.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com